GLP-1 therapies begin with motivation, long-term success depends on what happens when that motivation fluctuates.

This case study explores how Mighty, the AI health assistant within MyTherapy’s scalable direct-to-patient (DTP) ecosystem, protects persistence at predictable risk moments across the treatment lifecycle.

Inside the case study:

• Where GLP-1 persistence declines in real-world programs, and why traditional metrics miss it
• Why reminder-based adherence models are insufficient for long-term metabolic care
• How to address behavioral and emotional risk moments at scale without increasing compliance burden
• What a scalable, brand-ready DTP persistence architecture looks like across markets

Download the full case study to learn how GLP-1 programs can sustain long-term therapy persistence!